Rodney Ho, PhD, FAAAS, FAAPS

Professor,  Pharmaceutics, Bioengineering (Adjunct)
Director of the Targeted Long-Acting Combination Antiretroviral Therapy (TLC- ART) Program
University of Washington
Affiliate Member of Clinical Pharmacology, Fred Hutchinson Cancer Research Center
Affiliate Faculty, UW Center for AIDS Research

Dr. Ho is a professor of Pharmaceutics and UW Presidential Entrepreneurial Fellow. He holds appointments at the Institute of Translational Health Sciences, Center on Human Development & Disability and Fred Hutchinson Cancer Research Center. His research involves drug targeting and translational medicine.

He is noted for linking drug levels at target sites in the body to disease symptoms. He is an expert on translation of proteins into Biotherapeutics. Building on the knowledge of target cells and tissues pivotal to disease progressions, he develops nanomedicine and device-enabled technologies that make anti-infective agents such as HIV, pain and cancer medications more effective and safe.

He completed an Infectious Diseases Fellowship at Stanford University. Dr. Ho has been elected to Fellow status at the American Association for the Advancement of Science and the American Association of Pharmaceutical Scientists.

He has received some of his field’s highest honors, including the American Association of Colleges of Pharmacy’s Dawson Biotechnology Award and the AAPS Biotechnology Lifetime Achievement Award.

He has received continuous major research funding from the National Institutes of Health (NIH) that has led to over 100 publications related to improving drug delivery, transport, metabolism, safety and effectiveness.